MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
2.260
-0.070
-3.00%
Opening 14:30 05/15 EDT
OPEN
2.290
PREV CLOSE
2.330
HIGH
2.320
LOW
2.220
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
2.530
52 WEEK LOW
0.5137
MARKET CAP
1.00B
P/E (TTM)
-31.6084
1D
5D
1M
3M
1Y
5Y
1D
Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect Investor Conference
PUBT · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 4d ago
Lexicon Pharma Price Target Raised to $3.10/Share From $2.30 by Citigroup
Dow Jones · 4d ago
Lexicon Pharma Is Maintained at Buy by Citigroup
Dow Jones · 4d ago
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Benzinga · 4d ago
Lexicon price target raised to $3.10 from $2.30 at Citi
TipRanks · 4d ago
Weekly Report: what happened at LXRX last week (0504-0508)?
Weekly Report · 4d ago
Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained
TipRanks · 05/08 10:55
More
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.